Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Ligand Pharmaceuticals (LGNYZ) over the last 14 years, with Q2 2025 value amounting to $111000.0.

  • Ligand Pharmaceuticals' Current Deferred Revenue fell 9071.91% to $111000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $111000.0, marking a year-over-year decrease of 9071.91%. This contributed to the annual value of $1.3 million for FY2024, which is 458.27% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $111000.0 for Q2 2025, which was down 9071.91% from $101000.0 recorded in Q1 2025.
  • Ligand Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $25.1 million during Q1 2021, with a 5-year trough of $101000.0 in Q1 2025.
  • For the 5-year period, Ligand Pharmaceuticals' Current Deferred Revenue averaged around $5.8 million, with its median value being $1.2 million (2023).
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Current Deferred Revenue was 47664.22% (2021), while the steepest drop was 9777.82% (2021).
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Current Deferred Revenue stood at $654000.0 in 2021, then plummeted by 45.72% to $355000.0 in 2022, then soared by 244.23% to $1.2 million in 2023, then grew by 4.58% to $1.3 million in 2024, then plummeted by 91.31% to $111000.0 in 2025.
  • Its last three reported values are $111000.0 in Q2 2025, $101000.0 for Q1 2025, and $1.3 million during Q4 2024.